PMN vs. JAN, CARA, MRKR, OCUP, UNCY, BCTX, XLO, BOLT, NXTC, and APLM
Should you be buying ProMIS Neurosciences stock or one of its competitors? The main competitors of ProMIS Neurosciences include JanOne (JAN), Cara Therapeutics (CARA), Marker Therapeutics (MRKR), Ocuphire Pharma (OCUP), Unicycive Therapeutics (UNCY), BriaCell Therapeutics (BCTX), Xilio Therapeutics (XLO), Bolt Biotherapeutics (BOLT), NextCure (NXTC), and Apollomics (APLM). These companies are all part of the "pharmaceutical preparations" industry.
ProMIS Neurosciences (NASDAQ:PMN) and JanOne (NASDAQ:JAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.
JanOne has higher revenue and earnings than ProMIS Neurosciences.
In the previous week, JanOne had 1 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 2 mentions for JanOne and 1 mentions for ProMIS Neurosciences. JanOne's average media sentiment score of 0.50 beat ProMIS Neurosciences' score of 0.40 indicating that JanOne is being referred to more favorably in the news media.
ProMIS Neurosciences currently has a consensus price target of $8.00, indicating a potential upside of 321.05%. Given ProMIS Neurosciences' higher probable upside, research analysts plainly believe ProMIS Neurosciences is more favorable than JanOne.
ProMIS Neurosciences has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, JanOne has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500.
50.1% of ProMIS Neurosciences shares are owned by institutional investors. Comparatively, 6.3% of JanOne shares are owned by institutional investors. 10.3% of ProMIS Neurosciences shares are owned by insiders. Comparatively, 3.0% of JanOne shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ProMIS Neurosciences received 2 more outperform votes than JanOne when rated by MarketBeat users.
ProMIS Neurosciences' return on equity of 0.00% beat JanOne's return on equity.
Summary
ProMIS Neurosciences beats JanOne on 7 of the 13 factors compared between the two stocks.
Get ProMIS Neurosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProMIS Neurosciences Competitors List
Related Companies and Tools
